As­traZeneca hands off an­oth­er Am­gen-part­nered drug in a $1.5B deal with an ac­quis­i­tive Al­ler­gan

As­traZeneca is cash­ing in more of its R&D chips to­day, bag­ging a $250 mil­lion up­front and $1.27 bil­lion in mile­stones for an IL-23 out-li­cens­ing deal with the wheel­ing and deal­ing ex­ec­u­tive crew at Al­ler­gan. The pact marks an­oth­er ex­it out of a trou­bled 4-year-old col­lab­o­ra­tion with Am­gen.

Al­ler­gan, which is en­gaged in a deal fren­zy right now, gains ex­clu­sive glob­al rights to ME­DI2070, now in de­vel­op­ment for Crohn’s dis­ease and ul­cer­a­tive col­i­tis. And it’s com­mit­ted to a biobuck pack­age that breaks down with $435 mil­lion in launch pay­outs as well as $725 mil­lion for sales goals — if it makes its way to the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.